1. The NCCN Clinical Practice Guidelines in Oncology™ Acute Myeloid Leukemia (Version 2.2010). Available at www.nccn.org .
2. Roboz GJ: Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther 2007, 7(3):285–295.
3. Appelbaum FR, Gundacker H, Head DR, et al.: Age and acute myeloid leukemia. Blood 2006, 107(9):3481–3485.
4. • Fenaux P, Mufti GJ, Hellström-Lindberg E, et al.: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28(4):562–569. This paper highlights that treatment with 5-azacitidine of older AML patients who have a low bone marrow blast count can prolong overall survival when compared with conventional care regimens including induction chemotherapy, low-dose ara C, and BSC.
5. Feldman EJ, Ritchie EK, Gergis U, et al.: Evaluation of alternative “low intensity” regimens in elderly adults with acute myeloid leukemia (AML) [abstract]. Blood 2009, 114(22):Abstract 2066.